Latest news with #patientengagement
National Post
3 days ago
- Health
- National Post
OBIO® Supports A4i to Expand Canadian Presence Through New Partnership With Waypoint Centre for Mental Health Care
Article content TORONTO — Among patients with complex behavioural and mental health conditions, 23% face re-hospitalization within 30 days of discharge and 75% stop taking their medications after 18 months. Patient populations with severe mental illness require high patient engagement and support. To address this issue, A4i (App4Independence) offers patients an opportunity to play an active role in their care via a mobile application, promoting greater autonomy. Additionally, A4i's clinical portal provides their care team with the necessary insights to identify the risk of a relapse, allowing for earlier intervention. Article content With funding support from OBIO's Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence to adopt and implement the technology, A4i has secured a contract with the Waypoint Centre for Mental Health Care, one of Ontario's most highly specialized mental health facilities, which offers a range of mental health and addiction services, including specialized care for individuals living with severe mental illness. This partnership is a key milestone for A4i, as it advances commercialization and ROI demonstration in the Canadian healthcare landscape. Article content In 2024, A4i completed a successful evaluation at the Royal Ottawa Health Centre through OBIO's Early Adopter Health Network (EAHN™), making the technology available for wider dissemination among network healthcare organizations interested in acquiring A4i. With this partnership, A4i is broadening the adoption of its digital platform in Canada, expanding its commercialization with hospital partners in the province of Ontario. Article content 'By empowering people with the tools to manage their care, while giving clinicians meaningful, real-time insight, we're solving real-world challenges to improve continuity of care, reducing relapse risk, and supporting recovery beyond the walls of the hospital,' said Amos Adler, Co-Founder of A4i and CEO of MEMOTEXT. Article content The implementation of the A4i technology at Waypoint will be driven by A4i's 'health at home' initiative. As Waypoint covers a large geographical area, much of which is rural, patients often lack the necessary support within the community. Through the A4i app and portal, individuals with severe mental illness who are either transitioning back to the community from inpatient care or outpatients using community services, will now have another layer of support and connectivity with their care team to help them thrive. Article content 'This milestone partnership between the Waypoint Centre for Mental Health Care and A4i demonstrates the real-world benefits that can be achieved when digital innovation is pursued and critical technologies are deployed within the life sciences sector,' said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. 'By investing in organizations like OBIO ®, our government is committed to strengthening this leading industry, ensuring that we not only build on our past successes, but lay a foundation for competitiveness and economic growth for generations to come. We congratulate Waypoint, A4i, and OBIO ® on this collaboration and look forward to seeing their combined expertise support patients and care teams across Ontario.' Article content 'We're thrilled to harness technology to enhance our clients' recovery, with A4i offering timely resources and peer support to complement our team's care,' commented Kevin Young, Vice-President Medical Affairs and Chief of Staff at Waypoint. Article content 'The adoption of A4i's technology at Waypoint is a game changer for individuals with complex behavioural and mental health conditions, providing them with the tools and support they need to be empowered in their healthcare decisions and stay engaged with their healthcare team,' said Dr. Maura Campbell, President and CEO of OBIO ®. 'We are delighted to have facilitated the evaluation and adoption of this technology through our EAHN™ and LSCTC programs.' Article content ABOUT: Article content A4i Article content A4i (App4Independence) is a validated mobile app and clinical portal that supports individuals with schizophrenia and complex mental illnesses like opioid use disorder. A4i offers self-management features such as AI-driven wellness detection, adherence escalations, secure peer engagement, and a patented auditory hallucination detector. Designed to scale clinical decision support and peer support, A4i predicts relapse and risk. Founded in 2018 as a spin-off from the Centre for Addiction and Mental Health (CAMH), Canada's leading mental health and addiction research hospital, A4i was co-created with MEMOTEXT Corp. to empower recovery journeys for individuals facing challenges such as psychosis-related illness and opioid use disorders. Article content Article content Article content or contact Amos Adler CEO, A4i, Article content amos@ Article content Waypoint is a fully accredited academic and teaching hospital providing specialty mental health and addiction services and geriatric services for Simcoe County, Muskoka and central Ontario, as well as forensic mental health services for all of Ontario. As a regional provider of specialized services, the hospital has an extensive range of acute and longer-term psychiatric inpatient, outpatient and community-based program to meet the diverse needs of people of all ages, cultures and identities. Through our work and our Waypoint Research Institute, our team of forward-thinking experts provides leadership to the broader healthcare system. We harness partnership, innovation and research to advance understanding of mental health and addiction and improve lives locally and around the world. Article content ® Article content , a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, evaluates new technologies through its Early Adopter Health Network (EAHN™), supported by the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and implements successful solutions using critical technologies through its Life Sciences Critical Technologies and Commercialization (LSCTC) Centre of Excellence, supported by the Government of Ontario. OBIO Article content ® Article content on Article content LinkedIn Article content and Article content X Article content . Article content Article content Article content Article content Article content Contacts Article content MEDIA CONTACTS: Article content A4i (App4Independence) Article content Article content Amos Adler Article content Article content CEO Article content Article content amos@ Article content Waypoint Centre for Mental Health Care Article content Travis Mealing Article content Article content Communications Officer Article content Article content mediainquiry@ Article content OBIO ® Article content Article content Doriane Rey Article content Article content Article content Article content
Yahoo
26-05-2025
- Business
- Yahoo
Digital Therapeutics Market Analysis and Forecasts, 2025-2035: Rising Fundings and Investment in Digital Therapeutics and Expanding Applications Driving Opportunities
The global digital therapeutics market is rapidly transforming healthcare with evidence-based software and devices that enhance both physical and behavioral health management. Key drivers include increased accessibility, patient engagement, data insights, and reduced healthcare costs. Notable developments in the market feature major collaborations between prominent firms like Vida Health and Click Therapeutics. With challenges like data privacy and reimbursement hindrances, expanding applications and rising investment present vast opportunities for growth. This dynamic market is fueled by technological advances, cost-effectiveness, and expanding global reach, signifying a new era in personalized, patient-centered care. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Digital Therapeutics Market - A Global and Regional Analysis: Focus on Product Type, Application, Sales Channel, and Country - Analysis and Forecast, 2025-2035" report has been added to global digital therapeutics market includes clinically validated software and devices that are evidence-based. These tools are intended for the treatment of a wide range of diseases and conditions. Furthermore, digital therapeutics can be used either on their own or in combination with other devices to manage both physical and behavioural health issues. China led the Asia-Pacific digital therapeutics market in 2024, driven by its large population facing chronic conditions like diabetes, hypertension, and cardiovascular diseases. Digital therapeutics provides effective and accessible solutions for managing these health issues. The Chinese government acknowledges the potential of digital therapeutics and is actively supporting its development and adoption to improve healthcare delivery and outcomes. How can this report add value to an organization?Product/Innovation Strategy: The global digital therapeutics market is extensively segmented across various categories, such as product type, application, sales channel, and region. Each region undergoes a detailed analysis based on digital therapeutics product type, application, and sales channel. This segmentation offers readers a clear overview of which digital therapeutics segments currently dominate the market, and which ones are well-positioned for growth in the Strategy: Synergistic activities represented the largest share of key developments, with approximately 64.44% of all developments in the global digital therapeutics market occurring between January 2020 and November Strategy: The global digital therapeutics market is home to numerous established players, each offering product portfolios that address a wide array of conditions. Key players analysed and profiled in the study include prominent companies providing diverse digital therapeutics solutions for treatment, patient care, and preventive Dynamics Impact Analysis: Increased Accessibility of Care Improved Patient Engagement and Adherence Enhanced Data Collection and Analysis Reduced Costs of Healthcare Delivery Market Demand Drivers Multiple Benefits Provided by Digital Therapeutics over Traditional Treatment Continuous Technological Advancements Driving the Adoption of Digital Therapeutics Increasing Demand for Cost-Effective Solutions Creating a Demand for Digital Therapeutics Market Restraints: Data Privacy and Security Concerns Lack of Standardized Reimbursement Models Market Opportunities: Expanding Applications of Digital Therapeutics Rising Fundings and Investment in Digital Therapeutics Key Market Players Akili Interactive Labs, Inc. Lark Technologies, Inc. 2Morrow Inc. Click Therapeutics, Inc. Biofourmis Inc. Glooko, Inc. CureApp, Inc. Cognoa, Inc. Omada Health, Inc. Cara Care Neurotrack Technologies, Inc. Kaia Health ResMed Inc. Vida Health Vivante Health, Inc. Key Topics Covered: Executive SummaryScope of the Study1. Global Digital Therapeutics Market Overview1.1 Trends: Current and Future Impact Assessment1.1.1 Trend 1: Expansion across Therapeutic Area1.1.2 Trend 2: Integration with the Healthcare Ecosystem1.1.3 Trend 3: Utilization of Artificial Intelligence (AI) and Machine Learning (ML) with Digital Therapeutics1.2 Value Chain Analysis1.3 Funding Activities1.4 Regulatory Framework1.5 Patent Analysis2. Market Dynamics2.1.1 Impact Analysis2.1.2 Market Drivers2.1.3 Market Restraints2.1.4 Market Opportunities3. Global Digital Therapeutics Market Analysis (By Product Type), $Million, 2024-20353.1 Overview3.2 Growth-Share Matrix3.3 Product Type3.4 Software3.5 Devices4. Global Digital Therapeutics Market Analysis (By Application), $ Million, 2024-20354.1 Overview4.2 Growth-Share Matrix4.3 Application Summary4.4 Treatment/Patient Care-Related Applications4.4.1 Diabetes4.4.2 Neurological Disorders4.4.3 Smoking Cessation4.4.4 Chronic Respiratory Disorders4.4.5 Gastrointestinal Disorders4.4.6 Cardiovascular Disorders4.4.7 Medication Adherence4.4.8 Rehabilitation and Patient Care4.4.9 Others4.5 Preventive Applications4.5.1 Nutrition Management4.5.2 Lifestyle Management4.5.3 Others5. Global Digital Therapeutics Market Analysis (By Sales Channel), $Million, 2024-20355.1 Overview5.2 Sales Channel Summary5.3 Business-to-Business5.3.1 Insurance Providers/Corporate Employer5.3.2 Pharmaceutical Companies5.3.3 Others5.4 Business-to-Customer5.4.1 Patients5.4.2 Caregivers6. Global Digital Therapeutics Market Analysis (By Region), $ Million, 2024-20356.1 Regional Summary6.2 North America6.2.1 Regional Overview6.2.2 Driving Factors for Market Growth6.2.3 Factors Challenging the Market Growth6.2.4 U.S.6.2.5 Canada6.3 Europe6.3.1 Regional Overview6.3.2 Driving Factors for Market Growth6.3.3 Factors Challenging the Market Growth6.3.4 U.K.6.3.5 Germany6.3.6 France6.3.7 Italy6.3.8 Spain6.3.9 Rest-of-Europe6.4 Asia-Pacific6.4.1 Regional Overview6.4.2 Driving Factors for Market Growth6.4.3 Factors Challenging the Market Growth6.4.4 China6.4.5 Japan6.4.6 India6.4.7 Australia6.4.8 South Korea6.4.9 Rest-of-Asia-Pacific6.5 Latin America6.5.1 Regional Overview6.5.2 Driving Factors for Market Growth6.5.3 Factors Challenging the Market Growth6.5.4 Brazil6.5.5 Mexico6.5.6 Rest-of-Latin America6.6 Middle East and Africa6.6.1 Regional Overview6.6.2 Driving Factors for Market Growth6.6.3 Factors Challenging the Market Growth6.6.4 KSA6.6.5 U.A.E.6.6.6 Israel6.6.7 South Africa6.6.8 Rest-of-Middle East and Africa7. Global Digital Therapeutics Market - Competitive Benchmarking and Company Profiles7.1 Next Frontiers7.2 Competitive Analysis7.3 Global Ecosystem Glimpse7.4 Geographic Assessment7.4.1 Company Overview7.4.2 Product Portfolio7.4.3 Key Competitors7.4.4 Target Customers7.4.5 Analyst Perspective For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Digital Therapeutics Market Analysis and Forecasts, 2025-2035: Rising Fundings and Investment in Digital Therapeutics and Expanding Applications Driving Opportunities
The global digital therapeutics market is rapidly transforming healthcare with evidence-based software and devices that enhance both physical and behavioral health management. Key drivers include increased accessibility, patient engagement, data insights, and reduced healthcare costs. Notable developments in the market feature major collaborations between prominent firms like Vida Health and Click Therapeutics. With challenges like data privacy and reimbursement hindrances, expanding applications and rising investment present vast opportunities for growth. This dynamic market is fueled by technological advances, cost-effectiveness, and expanding global reach, signifying a new era in personalized, patient-centered care. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Digital Therapeutics Market - A Global and Regional Analysis: Focus on Product Type, Application, Sales Channel, and Country - Analysis and Forecast, 2025-2035" report has been added to global digital therapeutics market includes clinically validated software and devices that are evidence-based. These tools are intended for the treatment of a wide range of diseases and conditions. Furthermore, digital therapeutics can be used either on their own or in combination with other devices to manage both physical and behavioural health issues. China led the Asia-Pacific digital therapeutics market in 2024, driven by its large population facing chronic conditions like diabetes, hypertension, and cardiovascular diseases. Digital therapeutics provides effective and accessible solutions for managing these health issues. The Chinese government acknowledges the potential of digital therapeutics and is actively supporting its development and adoption to improve healthcare delivery and outcomes. How can this report add value to an organization?Product/Innovation Strategy: The global digital therapeutics market is extensively segmented across various categories, such as product type, application, sales channel, and region. Each region undergoes a detailed analysis based on digital therapeutics product type, application, and sales channel. This segmentation offers readers a clear overview of which digital therapeutics segments currently dominate the market, and which ones are well-positioned for growth in the Strategy: Synergistic activities represented the largest share of key developments, with approximately 64.44% of all developments in the global digital therapeutics market occurring between January 2020 and November Strategy: The global digital therapeutics market is home to numerous established players, each offering product portfolios that address a wide array of conditions. Key players analysed and profiled in the study include prominent companies providing diverse digital therapeutics solutions for treatment, patient care, and preventive Dynamics Impact Analysis: Increased Accessibility of Care Improved Patient Engagement and Adherence Enhanced Data Collection and Analysis Reduced Costs of Healthcare Delivery Market Demand Drivers Multiple Benefits Provided by Digital Therapeutics over Traditional Treatment Continuous Technological Advancements Driving the Adoption of Digital Therapeutics Increasing Demand for Cost-Effective Solutions Creating a Demand for Digital Therapeutics Market Restraints: Data Privacy and Security Concerns Lack of Standardized Reimbursement Models Market Opportunities: Expanding Applications of Digital Therapeutics Rising Fundings and Investment in Digital Therapeutics Key Market Players Akili Interactive Labs, Inc. Lark Technologies, Inc. 2Morrow Inc. Click Therapeutics, Inc. Biofourmis Inc. Glooko, Inc. CureApp, Inc. Cognoa, Inc. Omada Health, Inc. Cara Care Neurotrack Technologies, Inc. Kaia Health ResMed Inc. Vida Health Vivante Health, Inc. Key Topics Covered: Executive SummaryScope of the Study1. Global Digital Therapeutics Market Overview1.1 Trends: Current and Future Impact Assessment1.1.1 Trend 1: Expansion across Therapeutic Area1.1.2 Trend 2: Integration with the Healthcare Ecosystem1.1.3 Trend 3: Utilization of Artificial Intelligence (AI) and Machine Learning (ML) with Digital Therapeutics1.2 Value Chain Analysis1.3 Funding Activities1.4 Regulatory Framework1.5 Patent Analysis2. Market Dynamics2.1.1 Impact Analysis2.1.2 Market Drivers2.1.3 Market Restraints2.1.4 Market Opportunities3. Global Digital Therapeutics Market Analysis (By Product Type), $Million, 2024-20353.1 Overview3.2 Growth-Share Matrix3.3 Product Type3.4 Software3.5 Devices4. Global Digital Therapeutics Market Analysis (By Application), $ Million, 2024-20354.1 Overview4.2 Growth-Share Matrix4.3 Application Summary4.4 Treatment/Patient Care-Related Applications4.4.1 Diabetes4.4.2 Neurological Disorders4.4.3 Smoking Cessation4.4.4 Chronic Respiratory Disorders4.4.5 Gastrointestinal Disorders4.4.6 Cardiovascular Disorders4.4.7 Medication Adherence4.4.8 Rehabilitation and Patient Care4.4.9 Others4.5 Preventive Applications4.5.1 Nutrition Management4.5.2 Lifestyle Management4.5.3 Others5. Global Digital Therapeutics Market Analysis (By Sales Channel), $Million, 2024-20355.1 Overview5.2 Sales Channel Summary5.3 Business-to-Business5.3.1 Insurance Providers/Corporate Employer5.3.2 Pharmaceutical Companies5.3.3 Others5.4 Business-to-Customer5.4.1 Patients5.4.2 Caregivers6. Global Digital Therapeutics Market Analysis (By Region), $ Million, 2024-20356.1 Regional Summary6.2 North America6.2.1 Regional Overview6.2.2 Driving Factors for Market Growth6.2.3 Factors Challenging the Market Growth6.2.4 U.S.6.2.5 Canada6.3 Europe6.3.1 Regional Overview6.3.2 Driving Factors for Market Growth6.3.3 Factors Challenging the Market Growth6.3.4 U.K.6.3.5 Germany6.3.6 France6.3.7 Italy6.3.8 Spain6.3.9 Rest-of-Europe6.4 Asia-Pacific6.4.1 Regional Overview6.4.2 Driving Factors for Market Growth6.4.3 Factors Challenging the Market Growth6.4.4 China6.4.5 Japan6.4.6 India6.4.7 Australia6.4.8 South Korea6.4.9 Rest-of-Asia-Pacific6.5 Latin America6.5.1 Regional Overview6.5.2 Driving Factors for Market Growth6.5.3 Factors Challenging the Market Growth6.5.4 Brazil6.5.5 Mexico6.5.6 Rest-of-Latin America6.6 Middle East and Africa6.6.1 Regional Overview6.6.2 Driving Factors for Market Growth6.6.3 Factors Challenging the Market Growth6.6.4 KSA6.6.5 U.A.E.6.6.6 Israel6.6.7 South Africa6.6.8 Rest-of-Middle East and Africa7. Global Digital Therapeutics Market - Competitive Benchmarking and Company Profiles7.1 Next Frontiers7.2 Competitive Analysis7.3 Global Ecosystem Glimpse7.4 Geographic Assessment7.4.1 Company Overview7.4.2 Product Portfolio7.4.3 Key Competitors7.4.4 Target Customers7.4.5 Analyst Perspective For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Health
- Yahoo
Patient-centric trials: progress but gaps remain
Patient-centricity has become a buzzword in recent years, with companies touting more inclusive trial designs and bringing patients and advocates into early planning stages. On Clinical Trials Day 2025, the Clinical Trials Arena team asks: has the push for patient-centricity truly changed the way trials are run? Most clinical trial conferences now have a stream dedicated to patient engagement or patient centricity, and these streams are always filled with delegates who are ready to openly speak about how they can improve designs for patients, showing that the industry is starting to consider this way of thinking. These approaches have been more heavily adopted in the rare disease space, where enrolment is already a challenge. Ensuring that patients' opinions are considered in the protocols means it will likely be easier to enrol patients into the clinical trial. Sponsors need to understand why patients take part in research to really focus on patient-centricity, says Dr. Dominique Demolle, CEO of Cognivia, a company that develops analytical tools to optimise and accelerate clinical development. 'Patients who agree to participate in a clinical trial are doing it for the benefit of others and it has to represent what would be the real world,' Demolle explains. Demolle believes that change is happening, and this benefits both patients and stakeholders. In the past, strict protocols made finding eligible patients difficult. Today, sponsors are working with patient advocacy groups and patient leaders from the outset. While this has been an issue, Dr. Stacie Bell, chief clinical research officer of Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, says she has seen a push by sponsors to get to know what patients need and want from clinical trials to improve enrolment. 'Whether that be looking at a clinical trial protocol before it is actually finalised, or companies meeting those with a particular condition, that perspective can be incorporated into a clinical development programme,' Bells explains. According to Medable's Vice President of Patient Engagement, Jena Daniels, the onus cannot solely be on the sponsor. 'It's on every vendor, every partner, every CRO that they then choose to work with within their trial,' Daniels explains. That includes the regulators. Rare-disease patient Suzanne Harris, who works for marketing in SubjectWell notes that regulators including the US Food and Drug Administration (FDA) are pushing patient-centricity but have a way to go. 'The issue becomes, not many people know how to actually make it happen. I feel like companies are on the cusp, but the industry doesn't know how to pull it all together.' Not only in the US are regulators pushing this approach, but in Europe, advocacy groups and patient representatives have historically been included in European Medicines Agency (EMA) scientific review panels for protocols, showing the regulator's desire for sponsors to adopt patient-centric designs. While this has primarily been in rare diseases, it is now also happening in oncology. Not only is this something the regulators are providing guidance in, but in some cases will be considered in a drug approval, adds Cardiologist and CMO of Clinical Ink, an eSource solution company, Dr. Nicholas Alp. 'Many regulatory authorities now require evidence that you've done that as a sponsor – that you have had input from individual patients and advocacy groups and other experts to seek their feedback on what is proposed in the study, design the assessments that are planned to be used,' says Alp. Promising therapeutics have failed in the clinic not due to an initial lack of enrollment but due to patients dropping out of studies, highlighting the importance of retention when considering patient centricity. 'If we have poor adherence and poor retention, then we are at risk of having missing data, incomplete data or incorrect data and that is the focus of every scientific experiment,' Alp explains. The key to continuing the positive trend is to engage patients even earlier – in the pre-protocol stage to learn what endpoints are meaningful for patients, according to Harris. 'An example that I like to use is, if it's a headache trial and the medication makes you drowsy, but patients want to be able to live and work then sponsors are missing what a patient needs,' Harris says. 'They need to understand patient motivation – that is critical.' Bell agrees, adding that conversation with patients will help sponsors better understand how to design protocols. 'One example in lupus is that patients suffer fatigue or brain fog which is something that unless you're living with lupus, it's difficult to understand. If you're looking at a clinical trial endpoint that's looking at joints or skin manifestations and those types of things, not that they're not important, but sponsors need to understand what that lived experience is. There are things that are impactful and meaningful to those living with the disease.' Sponsors also need to find more ways to connect to patients to make more people aware of clinical trials, Bell continues. 'Sponsors need to hear the individual's voices about what they really need in clinical trials. That can come from meeting patients and that is critically important to having clinical trials be effective.' While it is important at an early stage to engage, keeping patients engaged throughout the study is also important, primarily by removing patient burden. Technology has been helping to improve patient-centricity and remove patient burden in trials by reducing site visits, Alp worries that some sponsors go too far when using decentralised models, which ends up adding burden again on patients. 'When it's possible to capture data from patients remotely, there is a temptation to just add more and more assessments remotely. While you think you're making life easier for the patient, actually, you're loading them up with assessments, and you're increasing the burden. Even in the hybrid and decentralised model, it's important that we follow what I think is like the first principle of clinical trial design - keep it simple and just collect the necessary data.' Not only are the patient's needs important, however, adds Daniels, who believes that sponsors and stakeholders also need to consider caregivers more to make trials more patient-centric. 'There's a whole support army behind every person participating in a trial, but these people can be unsung heroes behind the scenes supporting them. To round out that patient-centric approach, you must recognise the impact, influence, and participation that the caregivers have,' Daniels explains. 'Caregivers don't sign the consent form and may not be getting compensated for their time, but they are often just as invested as the patients, and it's such an important role and something we also need to highlight as part of that patient-centric approach.' Harris adds that sponsors also need to support sites and patients throughout the clinical trial because if sites are busy with administrative tasks, they have less time to focus on patient care. Daniels agrees that sites should also be at the centre if a sponsor wants to make a trial more patient-centric. Daniels says: 'If the sites themselves aren't fully supported, they end up spending time figuring out the technology and less time with the patient. When we talk about patient centricity, we're doing a disservice unless we also talk about supporting sites.' While patient centricity is important, it needs to be balanced by conducting an effective trial. 'A sponsor cannot embark on a protocol if it impacts efficacy and safety so if there is some pushback to that from a patient advocacy organisation, they would say no,' Demolle concludes. "Patient-centric trials: progress but gaps remain" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
12-05-2025
- Business
- Associated Press
DirectRx Pharmacy Partners With University of Michigan Ross School of Business for Consulting Studio Project Aimed at Improving Health Outcomes
TROY, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- As part of an in-depth research and data analytics project, master's students in the University of Michigan's Ross School of Business Master of Business Analytics program recently collaborated with DirectRx specialty pharmacy to reveal improved strategies for medication adherence. The results of the collaboration will enhance the company's commitment to data-driven decision making while opening new opportunities for long-term process improvement at DirectRx. The University of Michigan master's students partnered with DirectRx to first conduct market research, exploring how different sectors of the healthcare industry are leveraging data analytics to enhance patient care and improve service delivery. Their research focused on how demographic factors can influence medication refills. As a result, the group developed a data-driven model to predict medication adherence based on several factors. The Consulting Studio project team also developed a plan and suggested targeted interventions to enhance patient engagement and improve refill rates. 'This collaboration with University of Michigan students delivered not only innovative solutions but also fresh perspectives, directly informing our strategic decisions. It provided us with data-backed recommendations that will improve patient medication adherence,' said DirectRx President Alban Ivezaj. DirectRx, CONTACT: Marina Lekocaj, DirectRx (248) 273-0489
